

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

Assignment ID: TMI23524

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT OF THE ENTIRE INTEREST AND THE GOODWILL		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
Sagent Pharmaceuticals, Inc.		02/28/2023	Corporation: DELAWARE
<b>RECEIVING PARTY DATA</b>			
<b>Company Name:</b>	Sagent Pharmaceuticals		
<b>Street Address:</b>	1901 N. Roselle Road		
<b>Internal Address:</b>	Suite 450		
<b>City:</b>	Schaumburg		
<b>State/Country:</b>	ILLINOIS		
<b>Postal Code:</b>	60195		
<b>Entity Type:</b>	Corporation: WYOMING		
<b>PROPERTY NUMBERS Total: 6</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Registration Number:</b>	4088164	SSS	
<b>Registration Number:</b>	5835255	PREVENTIV MEASURES	
<b>Registration Number:</b>	4206146	SAGENT	
<b>Registration Number:</b>	4063565	DISCOVER INJECTABLES EXCELLENCE	
<b>Registration Number:</b>	3743423	SAGENT PHARMACEUTICALS	
<b>Registration Number:</b>	3729987	SSS	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>			
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	8047754391		
<b>Email:</b>	trademarks@mcguirewoods.com		
<b>Correspondent Name:</b>	Christel Harlacher		
<b>Address Line 1:</b>	800 East Canal Street		
<b>Address Line 4:</b>	Richmond, VIRGINIA 23219		
<b>NAME OF SUBMITTER:</b>	DEVON WESTRAY		
<b>SIGNATURE:</b>	DEVON WESTRAY		
<b>DATE SIGNED:</b>	02/13/2024		

OP \$165.00.00 77256745

**Total Attachments: 3**

source=Confirmatory IP Assignment\_Sagent Pharmaceuticals\_ Inc. (DE) to Sagent Ph#page1.tif

source=Confirmatory IP Assignment\_Sagent Pharmaceuticals\_ Inc. (DE) to Sagent Ph#page2.tif

source=Confirmatory IP Assignment\_Sagent Pharmaceuticals\_ Inc. (DE) to Sagent Ph#page3.tif

## CONFIRMATORY IP ASSIGNMENT AGREEMENT

**THIS CONFIRMATORY IP ASSIGNMENT AGREEMENT** (the “Agreement”) is effective as of February 28, 2023 (the “Effective Date”) and made by and between Sagent Pharmaceuticals, Inc., a Delaware corporation with an address at 1901 N. Roselle Road, Suite 450, Schaumburg, IL 60195 (“Assignor”), and Sagent Pharmaceuticals, a Wyoming corporation with an address at 1901 N. Roselle Road, Suite 450, Schaumburg, IL 60195 (the “Assignee” and collectively with the Assignor, the “Parties”).

**WHEREAS**, the Parties are parties to that certain Assignment and Assumption Agreement (“Assignment Agreement”) dated February 28, 2023 whereby Assignor assigned certain assets, including the Intellectual Property (as defined in Section 1.1 below), to Assignee, and the Parties hereby desire to confirm the assignment of Intellectual Property.

**NOW, THEREFORE**, in consideration of the mutual covenants set forth herein, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows:

1.1. Confirmation of Assignment of Intellectual Property. Effective as of the Effective Date, and on the terms and conditions set forth in the Assignment Agreement, Assignor hereby assigns, transfers, and conveys to Assignee, and Assignee acquires from Assignor, all right, title, and interest in and to the intellectual property identified on Schedule 1 attached hereto, together with all goodwill associated therewith, any pending applications and registrations therefor, patents, reissues, or extensions that may issue, including from foreign applications, divisions, continuations in whole or part, or substitute applications filed claiming the benefit of the patent applications therein, all common law trademark and trade name rights therein, the right to all past, current, and future royalties, fees, income, payments and other proceeds now or hereafter due or payable derived from the foregoing, and all rights to sue for any past, present, and future infringement or violation thereof and collect damages therefor (collectively, the “Intellectual Property”).

1.2. Recordal of Transfer. Assignor authorizes and requests the Commissioner of Patents and Trademarks of the United States of America, the U.S. Copyright Office, and the applicable officials of any other agencies or authorities, governmental or otherwise, to issue or transfer all of the Intellectual Property to Assignee or otherwise as Assignee may direct.

1.3. Conflict. To the extent any provision of this Agreement conflicts with any term of the Assignment Agreement, the terms of the Assignment Agreement shall control.

1.4. Successors and Assigns. The terms and provisions of this Agreement shall be binding upon, and inure to the benefit of, Assignor and Assignee, and each of their respective successors and assigns.

1.5. Severability. If any term or provision of this Agreement is invalid, illegal or unenforceable in any jurisdiction, such invalidity, illegality or unenforceability shall not affect any other term or provision of this Agreement or invalidate or render unenforceable


such term or provision in any other jurisdiction.

1.6. Counterparts. This Agreement may be executed and delivered in counterparts, each of which so executed and delivered shall be deemed to be an original and all of which shall constitute one and the same instrument.

**IN WITNESS WHEREOF**, each of the Parties have caused this Agreement to be signed as of the Effective Date.

**ASSIGNOR:**

**SAGENT PHARMACEUTICALS, INC.**  
A Delaware corporation


By: 

Name: Jeffrey Greve

Title: Chief Financial Officer

**ASSIGNEE:**

**SAGENT PHARMACEUTICALS**  
A Wyoming corporation

By: 

Name: Jeffrey Greve

Title: Chief Financial Officer

**SCHEDULE 1  
INTELLECTUAL PROPERTY**

(a) **Registered U.S. Trademarks:**

Trademark	Registration Date	Registration Number
SSS	01/17/12	4088164
PREVENTIV MEASURES	08/13/19	5835255
SAGENT	09/11/12	4206146
DISCOVER INJECTABLES EXCELLENCE	11/29/11	4063565
SAGENT PHARMACEUTICALS	01/26/10	3743423
SSS	12/22/09	3729987

(b) **U.S. Copyrights:**

Copyright	Registration Date	Registration Number
Heparin_20,000 USP units per mL - 1 mL package insert 40401.	May 11, 2010	VA0001720701